Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06640517 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis

Study acronym: PLANETA-KIDS
StatusActive, Not Recruiting
PhasePhase 3
SponsorBiocad
Started2024-08-08
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 27, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2026-05-22
Study Status, Oversight, Study Description v2
Study description-17 characters
Following screening, subjects will be randomized to receive either netakimab, placebo or adalimumab in a 2:1:2 ratio and enter the main study period. During the main study perio [...]
2025-06-18
Recruiting→Active, Not Recruiting Study Identification, Study Status, Contacts/Locations v1
Trial statusRecruiting→Active, Not Recruiting
Study sitesdetails revised at 14 of 14 sites
Study titlerevised
Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children withWith Moderate to Severe Plaque Psoriasis
2024-10-11
Original filing
Biocad
26 trials monitored
See all monitored trials
Psoriasis
418 trials monitored
See 17 trials at risk
The aim of the study is to evaluate the efficacy and safety of netakimab compared with placebo in a pediatric population of subjects over 6 years of age with moderate to severe plaque psoriasis. The study will have randomized, double-blind, placebo-controlled study with open-arm comparison.
Trial Details
NCT Number NCT06640517
Lead Sponsor Biocad
Conditions Plaque Psoriasis
Enrollment 140 participants
Start Date 2024-08-08
Primary Completion 2026-06 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2026-05-27